Showing results (1-10 of 177) with videos related to
Sort By:
Pageof 18
International Journal of Molecular Sciences|December 11, 2022
What Exactly Is Inflammation (and What Is It Not?)Bryan Oronsky, Scott Caroen, Tony ReidAmerican Journal of Cancer Research|May 9, 2022
The small molecule NLRP3 inhibitor RRx-001 potentiates regorafenib activity and attenuates regorafenib-induced toxicity in mice bearing human colorectal cancer xenograftsTony Reid, Bryan Oronsky, Nacer Abrouk, et al.International Journal of Medical Sciences|October 14, 2022
Superficial Venous-Associated Inflammation from Direct IV Administration of RRx-001 in RatsScott Caroen, Bryan Oronsky, Tony Reid, et al.Frontiers in Oncology|June 21, 2023
A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastomaHoward Fine, Tony Reid, Scott Caroen, et al.Frontiers in Oncology|June 14, 2023
RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonistBryan Oronsky, Lori Takahashi, Richard Gordon, et al.Recent Patents on Biotechnology|January 13, 2023
Patent and Marketing Exclusivities 101 for Drug DevelopersBryan Oronsky, Scott Caroen, Franck Brinkhaus, et al.Cancers|October 14, 2022
Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns HotBryan Oronsky, Brian Gastman, Anthony P Conley, et al.International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 5, 2022
Nucleocapsid as a next-generation COVID-19 vaccine candidateBryan Oronsky, Christopher Larson, Scott Caroen, et al.Frontiers in Immunology|March 24, 2023
Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)Tony Reid, Bryan Oronsky, Scott Caroen, et al.Journal of Cancer|August 1, 2022
A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)Bryan Oronsky, Nacer Abrouk, Scott Caroen, et al.Pageof 18